Buy Rating Affirmed for CARGO Therapeutics on Robust Trial Progress and Strong Market Potential

TipRanksApr 18 18:57

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

CARGO Therapeutics, Inc. (Nasdaq: CRGX) today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company's Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic clinical development experience in oncology, including cell therapy, with a proven track record in drug development, patient care and academic research.

GlobeNewswireApr 16 04:05

Cargo Therapeutics Reports Q4 Net Loss

Cargo Therapeutics (CRGX), which went public in November, reported late Thursday a Q4 net loss of $1.49 per diluted share. Three analysts polled by Capital IQ expected a loss of $1.62 per share. As ex

MT NewswiresMar 22 15:51

CARGO Therapeutics: Phase 2 Clinical Study FIRCE-1 of Firicabtagene Autoleucel (CRG-022) Is Rapidly Recruiting With 20 Sites Open to Date >CRGX

CARGO Therapeutics: Phase 2 Clinical Study FIRCE-1 of Firicabtagene Autoleucel (CRG-022) Is Rapidly Recruiting With 20 Sites Open to Date >CRGX

Dow JonesMar 22 04:18

Cargo Therapeutics Q4 2023 GAAP EPS $(1.49) Misses $(1.44) Estimate

Cargo Therapeutics (NASDAQ:CRGX) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(1.44) by 3.47 percent.

BenzingaMar 22 04:13

CARGO Therapeutics 4Q Loss/Shr $1.49 >CRGX

CARGO Therapeutics 4Q Loss/Shr $1.49 >CRGX

Dow JonesMar 22 04:09